Reglagene

Reglagene is a privately held, pre-revenue biotech founded in 2018 in San Diego, California, with a mission to transform the treatment of brain diseases by overcoming the formidable challenge of the blood-brain barrier. The company's core technology platform centers on designing low molecular weight, tubulin-targeting small molecules that passively cross the BBB and are not substrates for efflux pumps, enabling sustained therapeutic action in the brain. Its lead candidate, RGN6024, has demonstrated compelling preclinical efficacy in glioblastoma models and is advancing towards an IND filing. The company is led by a seasoned team with deep pharmaceutical industry and scientific expertise, positioning it to address a significant unmet need in neuro-oncology.

Proprietary platform for designing low molecular weight, orally available small-molecule therapies that passively cross the blood-brain barrier and evade efflux pumps, with an initial focus on tubulin-targeting agents for brain diseases.

Reglagene competes in the neuro-oncology space against other companies developing novel chemotherapies, targeted therapies, immunotherapies, and drug delivery technologies. Its direct differentiation lies in its specific chemical design for BBB penetration and efflux pump evasion, a niche approach compared to biologics or complex delivery systems. Standard-of-care chemotherapies like temozolomide and lomustine are its immediate benchmarks.